Shilpa Medicare enters Phase I Clinical Trial for its new biological entity
1st Nov 2021

Shilpa Medicare (SML), via its wholly owned subsidiary, Shilpa Biologicals (SBPL), has been permitted to conduct a Phase I human clinical study on its flagship novel product - recombinant Human Albumin (NavAlbumin), by the Central Drugs Standard Control Organisation (CDSCO).

The product, is a synthetically developed product as compared to the current process of drawing the same from blood plasma and is backed by granted global patent. It is designated a 'New Biological Entity' and is amongst the first indigenously developed novel molecules entering clinical studies - a significant milestone for the company and potentially large impact for the nation. The Company continues to strengthen its patent protection around the product to ring fence it from any potential competition.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.